2011-08-08 - EUSA Pharma announces launch of new Caphosol website
New study evaluating the effect of CAPHOSOL in reducing Oral Mucositis in head and neck cancer patients undergoing chemo-radiotherapy or radiotherapy
2011-01-05 - New CAPHOSOL study shows reduction in severity and duration of Oral Mucositis
2008-11-15 - Use of Caphosol Results in Low Rates of Oral Mucositis and Pain in Head/Neck Cancer Patients Receiving Chemoradiation
Caphosol Limits Occurrence and Severity of Oral Mucositis in Cancer Patients Receiving Chemoradiation
Share this Page
New Caphosol Website offers comprehensive resource on Oral Mucositis and Caphosol®.
EUSA Pharma is pleased to have launched the new more...
more news items
Caphosol, is a class 1 registered device, marked CE